Randomized Trial of Afatinib Plus Cetuximab Versus Afatinib Alone for First-Line Treatment of EGFR-Mutant Non–Small-Cell Lung Cancer: Final Results From SWOG S1403

RCT (n=168) found no difference in progression free survival in those receiving afatinib plus cetuximab compared with afatinib alone (11.9 vs 13.4 months, HR 1.01, p=0.94), though toxicity was greater (grade ≥ 3 adverse events:72% vs 40% respectively).

Source:

Journal of Clinical Oncology